Overcoming the blood-brain barrier: Functionalised chitosan nanocarriers

61Citations
Citations of this article
116Readers
Mendeley users who have this article in their library.

Abstract

The major impediment to the delivery of therapeutics to the brain is the presence of the blood-brain barrier (BBB). The BBB allows for the entrance of essential nutrients while excluding harmful substances, including most therapeutic agents; hence, brain disorders, especially tumours, are very difficult to treat. Chitosan is a well-researched polymer that offers advantageous biological and chemical properties, such as mucoadhesion and the ease of functionalisation. Chitosan-based nanocarriers (CsNCs) establish ionic interactions with the endothelial cells, facilitating the crossing of drugs through the BBB by adsorptive mediated transcytosis. This process is further enhanced by modifications of the structure of chitosan, owing to the presence of reactive amino and hydroxyl groups. Finally, by permanently binding ligands or molecules, such as antibodies or lipids, CsNCs have showed a boosted passage through the BBB, in both in vivo and in vitro studies which will be discussed in this review.

Cite

CITATION STYLE

APA

Caprifico, A. E., Foot, P. J. S., Polycarpou, E., & Calabrese, G. (2020). Overcoming the blood-brain barrier: Functionalised chitosan nanocarriers. Pharmaceutics, 12(11), 1–20. https://doi.org/10.3390/pharmaceutics12111013

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free